Lung cancer drug combo pushes survival to 21 months in big trial
Adding the drug tarlatamab helped people with advanced small-cell lung cancer live longer, a large trial found. Median survival rose to 21 months, from 12.7 months with durvalumab alone. Doctors heard the results at a cancer meeting in Madrid. The audience gave a standing ovation. Jacob Sands of Dana-Farber called it "a new standard of care."
Where this came from. One outlet reported this. We read it, then wrote the sixty words above.